Melbourne, Australia; 5 March 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD). [Read more…]
Types of Companies Competing within the Stem Cell Products Market
The stem cell products industry encompasses a diverse range of products and services. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult humans, stem and progenitor cells act as a repair system for the body, replenishing specialized cells. Since the discovery of stem cells more than 30 years ago, a robust market for stem cell products and services has emerged. [Read more…]
What are Placental Stem Cells and What are They Used For?
What are placental stem cells and what are placental stem cells used for? As placental stem cells get explored for a variety of therapeutic applications, these questions become increasingly important. The opportunity to collect placental stem cells is also a once in a lifetime opportunity. [Read more…]
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development.
WILMINGTON, Mass., February 20, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics. [Read more…]
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
Testing offers CBR families the opportunity to proactively seek additional information about their child’s health
TRUMBULL, Conn. and EL MONTE, Calif. — CooperSurgical®, a global leader in fertility and women’s health, and Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels. [Read more…]
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 334
- Next Page »